Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Alpine Immune Sciences

Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.

Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch

Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.

Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion

Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal

Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.

Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln

BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Direct.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Amgen

Ascendis Pharma

Cytokinetics

DexCom

Edwards Lifesciences

Tema Obesity & Cardiometabolic ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

Eli Lilly

Medtronic

Novo Nordisk

SPDR S&P 500 ETF Trust

Viking Therapeutics

Health Care Select Sector SPDR Fund

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can be a.

Vertex to Announce First Quarter 2024 Financial Results on May 6

Vertex Pharmaceuticals is starting a late-stage study for a promising candidate. In a best-case scenario, it could be as successful as the biotech's current top-seller.

This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?

It's been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term.

3 High-Growth Biotech Stocks Investors Shouldn't Sleep On in April

Moderna

Eli Lilly wowed patients and investors with its top-performing weight loss drugs. The big pharma company's stock has climbed in the triple digits over the past year thanks to its revenue growth.

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

UnitedHealth Group

The healthcare industry is full of promising opportunities for every type of investor. UnitedHealth Group's established presence spans insurance to managed care services.

Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul

United Therapeutics

The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.

3 Underappreciated Healthcare Stocks to Buy Now: April 2024

Gilead Sciences

The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.

Biotech Sector Nears Breakout: Will it Outperform in Q2?

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Costco

The "Magnificent Seven" are not the only stocks worth investing in. Vertex Pharmaceuticals and Eli Lilly are launching in-demand medicines.

Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two.

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

AbbVie

HCA Healthcare

Intuitive Surgical

These seven healthcare companies are industry and market leaders. They generally present excellent long-term prospects, too.

Meet The "Magnificent Seven" of Healthcare Stocks

Vertex Pharmaceuticals has an impeccable track record of innovation. The company recently reported important clinical progress.

1 Top Growth Stock to Buy and Hold Forever

Shopify

The rare disease drug and e-commerce markets both represent vast and growing opportunities. Vertex Pharmaceuticals is raking in profits and cash, and its product portfolio is rapidly evolving.

2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years

CRISPR Therapeutics

The sky is the limit for CRISPR Therapeutics. Eli Lilly is a growth machine that will not stop anytime soon.

3 Unstoppable Stocks to Buy Hand Over Fist in April

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet

Neurocrine Biosciences

“Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.

Three top U.S. biotech stocks to buy in April

BioNTech SE

Regeneron Pharmaceuticals

As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.

News for Vertex Pharmaceuticals Stock (VRTX)